South Korea-based Hyundai Bioscience has announced its readiness to supply its broad-spectrum antiviral drug XAFTY® in the event of Ebola or hantavirus outbreaks, subject to government or international request.

• Antiviral Profile: XAFTY® contains niclosamide, which has been reported to show inhibitory effects against Ebola and hantavirus in previous studies.
• Supply Readiness: The company states it can provide existing stock for emergency use under outbreak response requests from authorities or the World Health Organization (WHO).
• Clinical Status: XAFTY® is currently undergoing Phase 2 clinical trials for dengue fever in Vietnam.

This summary is based on a news article issued by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.